Phillip Securities lifts C&O Pharmaceutical (E92.SG) target price to $0.65 from $0.53, implying 13.7x FY11 P/E, after increasing FY11 earnings estimate by 8.6% to HK$175 million ($30.5 million) to assume stronger growth across all business segments, contributions from roll-out of new drugs, keeping Buy call, according to Dow Jones.
Phillip expects new drug Edaravone, used to aid neurological recovery, to be major earnings driver in coming years considering fewer than five manufacturers in China capable of producing it.
Broker notes market for this drug, which C&O expects to get regulatory approval for mass production by October, worth about RMB1 billion ($200 million) in 2009. Shares flat at $0.465.
Monday, August 30, 2010
C&O Pharma target raised to $0.65 by Phillip Securities
As reported at
Subscribe to:
Post Comments (Atom)
Popular Posts
-
I would like to apologize that sigining of my guestbook is not possible at the moment due to an unexpected bug. There is already 74 entries ...
-
Singapore's Land Transport Authority has just released an updated official MRT map including one additional station on the Downtown Line... -
*********** Try to sleep now, close your eyes Soon the birds would stop singing Twinkling stars, are shining bright They'll be watch...
-
POLLING Day next Saturday will be a public holiday as Singaporeans go to the polls to cast their votes in Singapore's 11th General Elect...
-
Installed FortiClient recently but the challenge in disabling the application/service from running automatically on every start-up annoyed m...
No comments:
Post a Comment
Do provide your constructive comment. I appreciate that.